Interleukins immunotherapy

K Role of interleukin-10 in specific immunotherapy. J Clin Invest 1998 102 98-106. 

Johnson BJ et al. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect Immunity 1998 66 2426-2433. 

Fehniger, T.A., Cooper, M.A., and Caligiuri, M.A. 2002. Interleukin-2 and interleukin-15 immunotherapy for cancer. Cytokine and Growth Factor Reviews 13(2), 169-183. 

Antony PA. Restifo NP CD4+CD25 + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immuno-ther 2005 28 120-128. 

Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT Allergen immunotherapy decreases interleukin-4 production in CD4+ T cells from allergic individuals. J Exp Med 1993 178 2123-2130. 

Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J Insect venom immunotherapy induces interleukin-10 production and a Th2- to-Thl shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997 27 1131-1139. 

Nasser SM, Ymg S, Meng 0, Kay AB, Ewan PW Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001 31 3704-3713. 

Reid I, Sharpe I, McDevitt J, Maxwell W, Emmons R, Tanner WA, Monson JR. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and inter-feron-2 alpha. Br J Cancer 1991 64(5) 915-8. 

Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, Lentjes E, Van Rood JJ, Cleton FJ, Osanto S. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993 ll(7) 1376-83. 

Sublingual immunotherapy Allergy Interleukin-2 receptor Soluble intercellular adhesion molecule-1 Immunoglobulin G4 sE-selectin Interleukin Immunoglobulin E... 

For the present open observation on sublingual immunotherapy (SLIT), nonspecific inflammatory markers were chosen, which are supposed to be involved in the allergic cascade and which can be measured by common ELISA techniques soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, soluble interleukin-2 receptor (sIL-2R), interleukin-12 (IL-12) and specific IgG4. Earlier investigations in this field were mostly performed on a smaller number of patients and the results are sometimes contradicting. 

Ohashi Y, Nakai Y, Sakamoto H, Ohno Y, Sugiura Y, Okamoto H, Tanaka A, Kakinoki Y, Kishimoto K, Hayashi M Serum levels of soluble interleukin-2 receptor in patients with perennial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol 1996 77 203-208. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, Masamoto T, Sakamoto H, Yamada K Ten-year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998 47 167-178. 

Galanis, E., Hersh, E.M., Stopeck, A.T., Gonzalez, R., Burch, P., Spier, C. et al. (1999) Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex phase I/II experience. J. Clin. Oncol., 17, 3313-3323. 

Tahara, H. and Lotze, M.T. (1995) Antitumor effects of interleukin-12 (IL-12) applications for the immunotherapy and gene therapy of cancer. Gene Then, 2, 96-106. 

Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer ceils and recombinant interleukin-2. Cancer Res 1985 45 3735-41. 

Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H. Severe hypo-vitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells. Cancer Res 1987 47(15) 4208-12. 

Fleischmann JD, Shingleton WB, Gallagher C, Ratnoff OD, Chahine A. Fibrinolysis, thrombocytopenia, and coagulation abnormahties comphcating high-dose interleukin-2 immunotherapy. J Lab Chn Med 1991 117(l) 76-82. 

Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991 68(7) 1538-44. 

Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988 30(3) 141-5. 

Birchfield GR, Ward JH, Redman BG, Flaherty L, Samlowski WE. Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for mahgnant melanoma. West J Med I990 I52(6) 7I4-I6. 

Feinfeld DA, D Agati V, Dutcher JP, Werfel SB, Lynn RI, Wiernik PH. Interstitial nephritis in a patient receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells. Am J Nephrol 1991 ll(6) 489-92. 

Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, EUas D, Rougier P, Escudier B, DuvUlard P, Pessayre D. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999 57(8) 951. ... 

Choyke PL, Miller DL, Lotze MT, Whiteis JM, Ebbitt B, Rosenberg SA. Delayed reactions to contrast media after interleukin-2 immunotherapy. Radiology 1992 183(1) 111-14. 

---